drugset

drugset / Trial / NCT00257478

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478 ↗

Phase 2 Completed Astellas Pharma Inc Astellas Pharma US, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Timeline

Start: —
Primary completion: —
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SEPANTRONIUM	Small molecule	—	—

Indications